GOVX
GeoVax Labs·NASDAQ
--
--(--)
--
--(--)
GOVX fundamentals
GeoVax Labs (GOVX) released its earnings on Nov 13, 2025: revenue was 0 (YoY -100.00%), met estimates; EPS was -7.75 (YoY +65.93%), missed estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-7.75
+65.93%
Report date
Nov 13, 2025
GOVX Earnings Call Summary for Q3,2025
- GEO-MVA Milestone: EMA guidance enables Phase III trial, with clinical manufacturing underway for early 2026 evaluation.
- CM04S1 Promise: Phase II data shows potential for immunocompromised patients, aligning with IDSA guidelines.
- Financial Focus: $5M cash balance supporting key programs, with exploration of nondilutive funding to extend runway.
- Strategic Growth: Increased collaboration interest for MVA supply chain and oncology partnerships.
- Risk Management: Net loss up 2% YoY due to clinical costs, but cost control efforts maintained R&D efficiency.
EPS
Actual | -273.75 | -363.75 | -108.75 | -78.75 | -116.25 | -836.25 | -127.5 | -67.5 | -63.75 | -52.5 | -56.25 | -82.5 | -120 | -98.5 | -61.75 | -49.75 | -22.75 | -21.8919 | -11.25 | -8.75 | -7.75 |
Forecast | -15 | -161.25 | -138.75 | -150 | -86.25 | -112.5 | -45 | -75 | -76.25 | -61.875 | -75.9375 | -69.4167 | -139 | -84.125 | -32.9 | -20.0625 | -16.4375 | -8.6875 | -6.7275 | ||
Surprise | 0.00% | -2325.00% | 0.00% | +51.16% | +16.22% | -457.50% | -47.83% | +40.00% | -41.67% | +30.00% | +26.23% | -33.33% | -58.02% | -41.90% | +55.58% | +40.86% | +30.85% | -9.12% | +31.56% | -0.72% | -15.20% |
Revenue
Actual | 415.00K | 251.00K | 110.42K | 79.71K | 30.41K | 165.00K | 82.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 301.00K | 2.79M | 882.50K | 1.62M | 876.15K | 0 |
Forecast | -- | 400.00K | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.33M | 2.97M | 1.67M | 776.08K | 0 |
Surprise | 0.00% | -37.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +108.91% | -70.25% | -2.89% | +12.90% | 0.00% |
Earnings Call
You can ask Aime
What is GeoVax Labs's latest dividend and current dividend yield?Did GeoVax Labs beat or miss consensus estimates last quarter?What is GeoVax Labs's gross profit margin?What were the key takeaways from GeoVax Labs's earnings call?What factors drove the changes in GeoVax Labs's revenue and profit?What does GeoVax Labs do and what are its main business segments?What guidance did GeoVax Labs's management provide for the next earnings period?What were the key takeaways from GeoVax Labs’s earnings call?
